122 related articles for article (PubMed ID: 34670090)
1. Gold(I) Bis(1,2,3-triazol-5-ylidene) Complexes as Promising Selective Anticancer Compounds.
Schlagintweit JF; Jakob CHG; Wilke NL; Ahrweiler M; Frias C; Frias J; König M; Esslinger EHJ; Marques F; Machado JF; Reich RM; Morais TS; Correia JDG; Prokop A; Kühn FE
J Med Chem; 2021 Nov; 64(21):15747-15757. PubMed ID: 34670090
[TBL] [Abstract][Full Text] [Related]
2. Gold(I) NHC Complexes: Antiproliferative Activity, Cellular Uptake, Inhibition of Mammalian and Bacterial Thioredoxin Reductases, and Gram-Positive Directed Antibacterial Effects.
Schmidt C; Karge B; Misgeld R; Prokop A; Franke R; Brönstrup M; Ott I
Chemistry; 2017 Feb; 23(8):1869-1880. PubMed ID: 27865002
[TBL] [Abstract][Full Text] [Related]
3. Cationic and Neutral N-Heterocyclic Carbene Gold(I) Complexes: Cytotoxicity, NCI-60 Screening, Cellular Uptake, Inhibition of Mammalian Thioredoxin Reductase, and Reactive Oxygen Species Formation.
Zhang C; Hemmert C; Gornitzka H; Cuvillier O; Zhang M; Sun RW
ChemMedChem; 2018 Jun; 13(12):1218-1229. PubMed ID: 29603648
[TBL] [Abstract][Full Text] [Related]
4. Chemistry and biology of two novel gold(I) carbene complexes as prospective anticancer agents.
Messori L; Marchetti L; Massai L; Scaletti F; Guerri A; Landini I; Nobili S; Perrone G; Mini E; Leoni P; Pasquali M; Gabbiani C
Inorg Chem; 2014 Mar; 53(5):2396-403. PubMed ID: 24547701
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of heterobimetallic gold(i) ferrocenyl-substituted 1,2,3-triazol-5-ylidene complexes as potential anticancer agents.
Aucamp D; Kumar SV; Liles DC; Fernandes MA; Harmse L; Bezuidenhout DI
Dalton Trans; 2018 Nov; 47(45):16072-16081. PubMed ID: 30276400
[TBL] [Abstract][Full Text] [Related]
6. Dinuclear gold(I) complexes based on carbene and diphosphane ligands: bis[2-(dicyclohexylphosphano)ethyl]amine complex inhibits the proteasome activity, decreases stem cell markers and spheroid viability in lung cancer cells.
Casagrande N; Borghese C; Corona G; Aldinucci D; Altaf M; Sulaiman AAA; Isab AA; Ahmad S; Peedikakkal AMP
J Biol Inorg Chem; 2023 Dec; 28(8):751-766. PubMed ID: 37955736
[TBL] [Abstract][Full Text] [Related]
7. Novel bis(thiosemicarbazones) of the 3,5-diacetyl-1,2,4-triazol series and their platinum(II) complexes: chemistry, antiproliferative activity and preliminary nephrotoxicity studies.
Matesanz AI; Hernández C; Rodríguez A; Souza P
Dalton Trans; 2011 Jun; 40(21):5738-45. PubMed ID: 21519595
[TBL] [Abstract][Full Text] [Related]
8. Triazole-based, optically-pure metallosupramolecules; highly potent and selective anticancer compounds.
Song H; Rogers NJ; Brabec V; Clarkson GJ; Coverdale JPC; Kostrhunova H; Phillips RM; Postings M; Shepherd SL; Scott P
Chem Commun (Camb); 2020 Jun; 56(47):6392-6395. PubMed ID: 32390012
[TBL] [Abstract][Full Text] [Related]
9. Gold(I) biscarbene complexes derived from vascular-disrupting combretastatin A-4 address different targets and show antimetastatic potential.
Muenzner JK; Biersack B; Kalie H; Andronache IC; Kaps L; Schuppan D; Sasse F; Schobert R
ChemMedChem; 2014 Jun; 9(6):1195-204. PubMed ID: 24648184
[TBL] [Abstract][Full Text] [Related]
10. Ferrocenyl-Coupled N-Heterocyclic Carbene Complexes of Gold(I): A Successful Approach to Multinuclear Anticancer Drugs.
Muenzner JK; Biersack B; Albrecht A; Rehm T; Lacher U; Milius W; Casini A; Zhang JJ; Ott I; Brabec V; Stuchlikova O; Andronache IC; Kaps L; Schuppan D; Schobert R
Chemistry; 2016 Dec; 22(52):18953-18962. PubMed ID: 27761940
[TBL] [Abstract][Full Text] [Related]
11. Novel NHC-coordinated ruthenium(II) arene complexes achieve synergistic efficacy as safe and effective anticancer therapeutics.
Chen C; Xu C; Li T; Lu S; Luo F; Wang H
Eur J Med Chem; 2020 Oct; 203():112605. PubMed ID: 32688202
[TBL] [Abstract][Full Text] [Related]
12. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties.
Rubbiani R; Kitanovic I; Alborzinia H; Can S; Kitanovic A; Onambele LA; Stefanopoulou M; Geldmacher Y; Sheldrick WS; Wolber G; Prokop A; Wölfl S; Ott I
J Med Chem; 2010 Dec; 53(24):8608-18. PubMed ID: 21082862
[TBL] [Abstract][Full Text] [Related]
13. A soluble bis-chelated gold(I) diphosphine compound with strong anticancer activity and low toxicity.
Wang Y; Liu M; Cao R; Zhang W; Yin M; Xiao X; Liu Q; Huang N
J Med Chem; 2013 Feb; 56(4):1455-66. PubMed ID: 23362983
[TBL] [Abstract][Full Text] [Related]
14. Gold(III) compounds-mediated inhibition of lung cancer cell proliferation.
Bostancioğlu RB; Kaya M; Koparal AT; Benkli K
Anticancer Drugs; 2016 Mar; 27(3):225-34. PubMed ID: 26825752
[TBL] [Abstract][Full Text] [Related]
15. Novel Anticancer NHC*-Gold(I) Complexes Inspired by Lepidiline A.
Curran D; Müller-Bunz H; Bär SI; Schobert R; Zhu X; Tacke M
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751607
[No Abstract] [Full Text] [Related]
16. Triazole-Based Half-Sandwich Ruthenium(II) Compounds: From
Lenis-Rojas OA; Cabral R; Carvalho B; Friães S; Roma-Rodrigues C; Fernández JAA; Vila SF; Sanchez L; Gomes CSB; Fernandes AR; Royo B
Inorg Chem; 2021 Jun; 60(11):8011-8026. PubMed ID: 33973771
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a cobalt (III) salen complex that induces apoptosis in Burkitt like lymphoma and leukemia cells, overcoming multidrug resistance in vitro.
Hopff SM; Onambele LA; Brandenburg M; Berkessel A; Prokop A
Bioorg Chem; 2020 Nov; 104():104193. PubMed ID: 32947134
[TBL] [Abstract][Full Text] [Related]
18. Heterobimetallic propargyl gold complexes with π-bound copper or silver with enhanced anticancer activity.
Johnson A; Marzo I; Gimeno MC
Dalton Trans; 2020 Aug; 49(33):11736-11742. PubMed ID: 32797134
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, characterization, and in vitro antitumor properties of tris(hydroxymethyl)phosphine copper(I) complexes containing the new bis(1,2,4-triazol-1-yl)acetate ligand.
Marzano C; Pellei M; Colavito D; Alidori S; Lobbia GG; Gandin V; Tisato F; Santini C
J Med Chem; 2006 Dec; 49(25):7317-24. PubMed ID: 17149861
[TBL] [Abstract][Full Text] [Related]
20. Novel gold(I) complexes induce apoptosis in leukemia cells via the ROS-induced mitochondrial pathway with an upregulation of Harakiri and overcome multi drug resistances in leukemia and lymphoma cells and sensitize drug resistant tumor cells to apoptosis in vitro.
Ahrweiler-Sawaryn MC; Biswas A; Frias C; Frias J; Wilke NL; Wilke N; Berkessel A; Prokop A
Biomed Pharmacother; 2023 May; 161():114507. PubMed ID: 36958194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
